Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and chemotherapy improved progression-free survival but did not achieve ...

Extended collaboration will further explore the capabilities of Medidata Platform from early-phase trials to post-marketing ...

In this video interview, Dipanwita Das, CEO & co-founder at Sorcero, looks back to 2024 and discusses some of the industry’s ...

In this video interview, Dipanwita Das, CEO & co-founder at Sorcero, highlights increased data management, DE&I, and ...

In the Phase I dose escalation portion, which evaluated the combination in participants with small cell lung cancer, the first patient treated attained partial remission.

Phase III Vivacity-MG3 trial shows that nipocalimab, an investigational FcRn blocker, significantly the improves symptoms of generalized myasthenia gravis with a manageable safety profile.

Phase III CheckMate -8HW trial shows the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) significantly improved progression-free survival and overall response rates in patients with ...

Being evaluated for the treatment of metastatic colorectal cancer, the combination regimen achieved an objective response rate of 61% compared to 40% for investigator’s choice of chemotherapy. Pfizer ...

In this video interview, Dipanwita Das, CEO & co-founder at Sorcero, highlights trial startup timelines and workforce development as key areas of focus for clinical operations professionals in 2025.